The FDA has given Salix Pharmaceuticals and Progenics Pharmaceuticals the go-ahead to market their subcutaneous injectable drug Relistor (methylnaltrexone) for opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
The FDA has given Salix Pharmaceuticals and Progenics Pharmaceuticals the go-ahead to market their subcutaneous injectable drug Relistor (methylnaltrexone) for opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
An estimated 27 million US patients take opioids for chronic pain. But patients taking those drugs are often plagued by constipation.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
The UK major's asthma drug gets a key expanded approval.
